BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10519451)

  • 1. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients.
    Hübner GI; Eismann R; Sziegoleit W
    Ther Drug Monit; 1999 Oct; 21(5):536-9. PubMed ID: 10519451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy.
    Vidal E; Cantarell C; Capdevila L; Monforte V; Roman A; Pou L
    Pharmacol Toxicol; 2000 Oct; 87(4):182-4. PubMed ID: 11097273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolic acid plasma concentrations: influence of comedication.
    Pou L; Brunet M; Cantarell C; Vidal E; Oppenheimer F; Monforte V; Vilardell J; Roman A; Martorell J; Capdevila L
    Ther Drug Monit; 2001 Feb; 23(1):35-8. PubMed ID: 11206040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.
    Falck P; Vethe NT; Asberg A; Midtvedt K; Bergan S; Reubsaet JL; Holdaas H
    Nephrol Dial Transplant; 2008 Mar; 23(3):1048-53. PubMed ID: 17956893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Fernandes FB; Casarini DE; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2009 Feb; 23(1):137-45. PubMed ID: 19267777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.
    Filler G; Zimmering M; Mai I
    Pediatr Nephrol; 2000 Feb; 14(2):100-4. PubMed ID: 10684356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
    Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
    J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
    Filler G; Foster J; Berard R; Mai I; Lepage N
    Transplant Proc; 2004 Jun; 36(5):1327-31. PubMed ID: 15251324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?
    Meiser BM; Groetzner J; Kaczmarek I; Landwehr P; Müller M; Jung S; Uberfuhr P; Fraunberger P; Stempfle HU; Weis M; Reichart B
    Transplantation; 2004 Aug; 78(4):591-8. PubMed ID: 15446320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.